Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
US WorldMeds
US WorldMeds initiates phase 3 trial of lofexidine for treating opiate withdrawal symptoms
November 7th, 2006
US WorldMeds, a Kentucky-based specialty pharmaceutical company, announced that it is enrolling patients in a phase 3 clinical trial, USWM-001, investigating the use of lofexidine hydrochloride (lofexidine) for the treatment of opiate withdrawal symptoms in opiate dependent individuals. If approved by the Food and Drug Administration (FDA), lofexidine would be the first non-addictive, non-narcotic treatment for relieving the withdrawal symptoms associated with opiate detoxification approved in the United States. Investigators are currently recruiting 264 patients to participate in the in-patient, randomized, double-blind trial that will be conducted...
Source: Drug Law Weekly (2006-11-07)
|
